How to talk with parents about the recent Pfizer/BioNTech news for the youngest kids

Video

Editor-in-chief Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, discusses how to help parents who are worried or nervous about the delay in the expansion of the Pfizer/BioNTech vaccine to children aged 6 months to younger than 4 years.

Editor-in-chief Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, discusses how to help parents who are worried or nervous about the delay in the expansion of the Pfizer/BioNTech vaccine to children aged 6 months to younger than 4 years.

Related Videos
Juanita Mora, MD
Rupa Wong, MD | Image Credit: Rupa Wong, MD
Tina Tan, MD, FAAP, FIDSA, FPIDS, editor in chief, Contemporary Pediatrics, professor of pediatrics, Feinberg School of Medicine, Northwestern University, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital of Chicago
John Bradley, MD
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Pfizer's infant RSV vaccine receives FDA Advisory Committee's support | Image Credit: Dr_Microbe - Image Credit: Dr_Microbe
Related Content
FDA approves tovorafenib for most common form of childhood brain tumor | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA approves tovorafenib for most common form of childhood brain tumor

April 24th 2024
Article

This decision from the federal agency marks the first FDA approval of a systemic therapy to treat patients with pediatric LGG with BRAF rearrangements, including fusions.

Ustekinumab biosimilar approved to treat moderate to severe plaque psoriasis | Image Credit: © Calin - © Calin - stock.adobe.com.

Ustekinumab biosimilar approved to treat moderate to severe plaque psoriasis

April 23rd 2024
Article

The biosimilar to ustekinumab is approved for patients 6 years and up, and is expected to be marketed on or after February 21, 2025.

CRL issued for pz-cel as potential recessive dystrophic epidermolysis bullosa treatment | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

CRL issued for pz-cel as potential recessive dystrophic epidermolysis bullosa treatment

April 23rd 2024
Article

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

FDA accepts BLA for meningococcal ABCWY vaccine, target action date set | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

FDA accepts BLA for meningococcal ABCWY vaccine, target action date set

April 16th 2024
Article

The 5-in-1 vaccine candidate has the potential to reduce shots and simplify the immunization process.

Image Credit: © Calin - © Calin - stock.adobe.com.

FDA approves dolutegravir/lamivudine to treat HIV infection in adolescents

April 8th 2024
Article

The treatment is approved for adolescents aged 12 years and older.

Zevtera approved for community-acquired bacterial pneumonia in infants, adolescents, teens | Image Credit: © Calin - © Calin - stock.adobe.com.

Zevtera approved for community-acquired bacterial pneumonia in infants, adolescents, teens

April 4th 2024
Article

The pediatric approval to treat CABP is 1 of 3 indications approved by the FDA.

© 2024 MJH Life Sciences

All rights reserved.